Navigation Links
Visceral Leishmaniasis: Successful Vaccine Trial In Dogs

Visceral leishmaniasis, which is the most severe form of that group of diseases, affects 500 000 people in the world each year. It is caused by a protozoan, Leishmania infantum, transmitted by sand fly bites. There is no vaccine for this disease, which can rapidly lead to death if no treatment is given. In the most heavily affected areas, the dog population is hit heavily by infection. It acts as parasite reservoir for humans. Development of a vaccine for dogs could help brake transmission of the disease to humans, by reducing this reservoir. Such prevention treatment has just been tested successfully on dogs by an IRD team in Montpellier, in conjunction with the Rocher veterinary clinic (La Garde, Var) and the biopharmaceutical company Bio Véto Test (La Seyne-Sur-Mer, Var). The first results showed total lasting protection of these animals against the disease, could open the way towards the development of a human vaccine.

Visceral leishmaniasis, which is the most severe form of the leishmaniases, hits an annual total of 500 000 people, mostly in the developing countries. It is caused by the parasite Leishmania infantum. A flagellate protozoan, it uses as vector an insect resembling a midge, the sand fly, colonizing the intestine and then the salivary glands. The female insect feeds on mammals?blood. It can thus pass the parasite on to humans by a single bite. Once in the blood stream, L. infantum passes into particular cells of the immune system, the macrophages. These eventually burst, releasing the parasites which move on to penetrate other cells. The infected subject suffers bouts of fever, anaemia, enlarged spleen and liver, and weight loss. In the absence of treatment, these clinical signs usually announce a fatal outcome.

The sand fly sucks blood from mammals other than humans. This is how, right around the Mediterranean rim, 5 million dogs, a proportion of from 1 to 42 % depending on the area, are affected by visceral leishmaniasis. These anim
'"/>

Source:Institut de Recherche Pour le D茅veloppement


Page: 1 2 3 4

Related biology news :

1. Successful Test Of Single Molecule Switch Opens The Door To Biomolecular Electronics
2. Penn Surgeons Use Completely Robotic Surgery to Successfully Treat Prostate Cancer
3. Successful cell engineering may lead to mad cow prevention, say researchers
4. Successful transplantation from pig embryos to mice
5. Successful lung cancer surgery not enough to break nicotine dependence in many smokers
6. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
7. Live Recombinant Adenovirus Vaccine Technique Explored
8. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
9. NIAID Initiates Trial of Experimental Avian Flu Vaccine
10. Study Models Impact Of Anthrax Vaccine
11. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Visceral Leishmaniasis Successful Vaccine Trial Dogs

(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
(Date:2/5/2015)... January 28, 2015 New Market ... And Segment Forecasts To 2020 has Been Added to ... market is expected to reach USD 5.10 billion by ... Research, Inc. IR cameras help identify the site of ... to witness surging demand in medical imaging applications. They ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... BEER-SHEVA, ISRAEL, May 3, 2010 Ben-Gurion University ... strain which produces large amounts of a polyunsaturated fatty ... blood cholesterol level, reducing the risk for heart attacks. ... Biotechnology Lab in the Jacob Blaustein Institutes for Desert ...
... keep the planet cool, but rising levels of carbon dioxide ... According to a new study by researchers at the Carnegie ... of the warming from increased carbon dioxide is due to ... to carbon dioxide,s better-known effect as a heat-trapping greenhouse gas. ...
... (May 3, 2010) Advances in energy conservation, better ... breakthroughs in understanding diseases: These are just a few ... be enabled by an upgrade to the Advanced Photon ... Argonne National Laboratory., DOE today announced formal approval for ...
Cached Biology News:Ben-Gurion U researchers isolate microalgal strain that could reduce cholesterol 2CO2 effects on plants increases global warming 2CO2 effects on plants increases global warming 3Upgrade to advanced photon source announced by DOE 2Upgrade to advanced photon source announced by DOE 3
(Date:3/4/2015)... , March 4, 2015 In an article ... UPMC Center for Health Security review the clinical aspects ... be used as bioweapons. The article, "Clinical Management of ... on the website of the New England Journal ... Eric Toner , and Tom Inglesby—review the clinical ...
(Date:3/4/2015)... -- Brooklyn residents now have a new place to go ... Nunzio Saulle , M.D., a board-certified physiatrist, is ... Physical Medicine and Rehabilitation (PM&R) practice in ... Health Plus Management, LLC is managing the day-to-day operations ... Avenue. This new PM&R practice will treat patients suffering ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Biomarkers - Technologies, ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
(Date:3/4/2015)... , March 4, 2015 /CNW/ - Resverlogix ... it has completed a collaborative research program ... analytics.  Using Fast Collective Evolution Technology (FACET), ... including all measurements obtained from each of ... Phase 2 clinical trials ASSERT, SUSTAIN and ...
Breaking Biology Technology:Latest Clinical Information On Bioterrorism Threats 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4
... ST. LOUIS, Oct. 25 Sigma-Aldrich(TM) (Nasdaq:,SIAL), a ... biotechnology products to the world,s researchers, and Oxford,BioMedica ... today that,they received a key order confirming the ... BioMedica and licensed exclusively in,the research field to ...
... Study Planned, WESTMINSTER, Colo., Oct. 25 ... company focused on,the development and commercialization of small ... that results from three PDX,studies were presented as ... 2007 in San Francisco, California. The posters,described the ...
... XTL Biopharmaceuticals,Ltd. (NASDAQ: XTLB )(LSE: XTL)(TASE: XTL) ... with institutional investors relating to,a private placement of ... of,ordinary shares, represented by American Depositary Receipts (ADRs). ... Sciences Fund, Quogue,Capital LLC, SCO Capital Partners and ...
Cached Biology Technology:Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 2Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 3Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference 2Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference 3Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference 4XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors 2XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors 3
... Ingredients (g/L):,Tryptone, 10 ,Yeast extract, 5 ... 0.3 ,Ferric ammonium citrate, 0.5 ,IPTG, ... water soluble, autoclavable chromogenic substrate for ... by -galactosidase generates a black insoluble ...
... form: Lyophilized powder containing ... Unit Definition: One unit ... 2-phosphoglycerate to phospho(enol)pyruvate per ... 25 C. Chem comp: ...
... CoA ligase (AMP forming), Acetate thiokinase ... content. Physical form: Lyophilized powder ... reduced glutathione Preparation Unit Definition: ... S-acetyl coenzyme A from acetate, ATP and ...
... a new product number, created to ... showing no availability yet, please order ... or contact customer service for assistance. ... mm, No. of sidearm 4 ...
Biology Products: